The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.
Overcoming T cell exhaustion in infection and cancer
Open accessAbstract
Inhibitors of the PD-1:PD-L1 pathway, a central regulator of T cell exhaustion, have been recently shown to be effective for treatment of different cancers. However, clinical responses are mixed, highlighting the need to better understand the mechanisms of action of PD-1:PD-L1, the role of this pathway in immunity to different tumors, and the molecular and cellular effects of PD-1 blockade. Here we review the molecular regulation of T cell exhaustion, placing recent findings on PD-1 blockade therapies in cancer in the context of the broader understanding of the roles of the PD-1:PD-L1 pathway in T cell exhaustion during chronic infection. We discuss the current understanding of the mechanisms involved in reversal T cell exhaustion, and outline critical areas of focus for future research, both basic and clinical.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 23×
“Studies in preclinical models have greatly contributed to our understanding of the PD-1 pathway in the regulation of T cell immunity [3, 37, 96].”
BackgroundInfluentialSelf-citationRestoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Self-citationCancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Self-citationMPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Bellmunt, J., Burris, H. A., Petrylak, D. P., Teng, S.-L., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,381
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Control of Viremia in Simian Immunodeficiency Virus Infection by CD8 + Lymphocytes
Schmitz, J. E., Kuroda, M. J., Santra, S., Sasseville, V. G., Simon, M. A., Lifton, M. A., Racz, P., Tenner-Racz, K., Dalesandro, M., Scallon, B. J., et al. (1999) · Science · doi:10.1126/science.283.5403.857 · Cited by 2,187
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103
Self-citationBlackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062
Self-citationViral Immune Evasion Due to Persistence of Activated T Cells Without Effector Function
Zajac, A. J., Blattman, J. N., Murali-Krishna, K., Sourdive, D. J. D., Suresh, M., Altman, J. D., & Ahmed, R. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2205 · Cited by 1,978
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974 · cited 6×
“Examples of such responses include protection from rechallenge with MCA-induced sarcoma cell lines F244 and d42m1-T3 following PD-1 blockade, colon carcinoma (CT26) after PD-L1 and TIGIT co-blockade, and a B16-F10 derived cell line called Res 499 for PD-L1 and CTLA-4 co-blockade in combination with radiation therapy […”
BackgroundInfluentialCTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931
Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
Transcriptional control of effector and memory CD8+ T cell differentiation
Kaech, S. M., & Cui, W. (2012) · Nature Reviews Immunology · doi:10.1038/nri3307 · Cited by 1,628
Wherry, E. J., Blattman, J. N., Murali-Krishna, K., van der Most, R., & Ahmed, R. (2003) · Journal of Virology · doi:10.1128/jvi.77.8.4911-4927.2003 · Cited by 1,610
Self-citationSchwartz, R. H. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141110 · Cited by 1,487
Jin, X., Bauer, D. E., Tuttleton, S. E., Lewin, S., Gettie, A., Blanchard, J., Irwin, C. E., Safrit, J. T., Mittler, J., Weinberger, L., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.6.991 · Cited by 1,407
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.11.006 · Cited by 1,354
Self-citationTargeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.12.009 · Cited by 1,329
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314
Fourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100637 · Cited by 1,307
Analysis of Successful Immune Responses in Persons Infected with Hepatitis C Virus
Lechner, F., Wong, D. K. H., Dunbar, P. R., Chapman, R., Chung, R. T., Dohrenwend, P., Robbins, G., Phillips, R., Klenerman, P., & Walker, B. D. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.9.1499 · Cited by 1,269
Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin
Intlekofer, A. M., Takemoto, N., Wherry, E. J., Longworth, S. A., Northrup, J. T., Palanivel, V. R., Mullen, A. C., Gasink, C. R., Kaech, S. M., Miller, J. D., et al. (2005) · Nature Immunology · doi:10.1038/ni1268 · Cited by 1,266
Self-citationChemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H., & Riley, J. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.945 · Cited by 1,246
The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
Johnston, R. J., Comps-Agrar, L., Hackney, J., Yu, X., Huseni, M., Yang, Y., Park, S., Javinal, V., Chiu, H., Irving, B., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.018 · Cited by 1,194
Homeostasis of Naive and Memory T Cells
Surh, C. D., & Sprent, J. (2008) · Immunity · doi:10.1016/j.immuni.2008.11.002 · Cited by 1,193
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
Yadav, M., Jhunjhunwala, S., Phung, Q. T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T. K., Fritsche, J., Weinschenk, T., et al. (2014) · Nature · doi:10.1038/nature14001 · Cited by 1,186
Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112741 · Cited by 1,161
CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection
Matloubian, M., Concepcion, R. J., & Ahmed, R. (1994) · Journal of Virology · doi:10.1128/jvi.68.12.8056-8063.1994 · Cited by 1,157
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
Lee, P. P., Yee, C., Savage, P. A., Fong, L., Brockstedt, D., Weber, J. S., Johnson, D., Swetter, S., Thompson, J., Greenberg, P. D., et al. (1999) · Nature Medicine · doi:10.1038/9525 · Cited by 1,113
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,111
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity
Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., Rietz, C., Flies, D. B., Lau, J. S., Zhu, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.1089.65.3 · Cited by 1,018
Interleukin-10 determines viral clearance or persistence in vivo
Brooks, D. G., Trifilo, M. J., Edelmann, K. H., Teyton, L., McGavern, D. B., & Oldstone, M. B. A. (2006) · Nature Medicine · doi:10.1038/nm1492 · Cited by 923
Progenitor and Terminal Subsets of CD8 + T Cells Cooperate to Contain Chronic Viral Infection
Paley, M. A., Kroy, D. C., Odorizzi, P. M., Johnnidis, J. B., Dolfi, D. V., Barnett, B. E., Bikoff, E. K., Robertson, E. J., Lauer, G. M., Reiner, S. L., et al. (2012) · Science · doi:10.1126/science.1229620 · Cited by 902
Self-citationMatsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P., Beck, A., Miller, A., Tsuji, T., Eppolito, C., Qian, F., Lele, S., Shrikant, P., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003345107 · Cited by 859
Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection
Jin, H.-T., Anderson, A. C., Tan, W. G., West, E. E., Ha, S.-J., Araki, K., Freeman, G. J., Kuchroo, V. K., & Ahmed, R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009731107 · Cited by 858
The Transcription Factor NFAT Promotes Exhaustion of Activated CD8 + T Cells
Martinez, G. J., Pereira, R. M., Äijö, T., Kim, E. Y., Marangoni, F., Pipkin, M. E., Togher, S., Heissmeyer, V., Zhang, Y. C., Crotty, S., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.01.006 · Cited by 857 · cited 1×
“Moreover, NFAT binding in the absence of AP-1 appears to promote expression of some features of an exhausted transcriptional program [128].”
BackgroundExhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients
Baitsch, L., Baumgaertner, P., Devêvre, E., Raghav, S. K., Legat, A., Barba, L., Wieckowski, S., Bouzourene, H., Deplancke, B., Romero, P., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46102 · Cited by 845
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
Ohaegbulam, K. C., Assal, A., Lazar-Molnar, E., Yao, Y., & Zang, X. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.10.009 · Cited by 843
Dutton, R. W., Bradley, L. M., & Swain, S. L. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.201 · Cited by 832
Sheppard, K.-A., Fitz, L. J., Lee, J. M., Benander, C., George, J. A., Wooters, J., Qiu, Y., Jussif, J. M., Carter, L. L., Wood, C. R., et al. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.07.083 · Cited by 791
PD-1 signaling in primary T cells
Riley, J. L. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00767.x · Cited by 778
Blank, C., Brown, I., Peterson, A. C., Spiotto, M., Iwai, Y., Honjo, T., & Gajewski, T. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3259 · Cited by 772
Gallimore, A., Glithero, A., Godkin, A., Tissot, A. C., Plückthun, A., Elliott, T., Hengartner, H., & Zinkernagel, R. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.9.1383 · Cited by 763
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal
Fife, B. T., Pauken, K. E., Eagar, T. N., Obu, T., Wu, J., Tang, Q., Azuma, M., Krummel, M. F., & Bluestone, J. A. (2009) · Nature Immunology · doi:10.1038/ni.1790 · Cited by 759
Self-citationPersistent LCMV infection is controlled by blockade of type I interferon signaling
Teijaro, J. R., Ng, C., Lee, A. M., Sullivan, B. M., Sheehan, K. C. F., Welch, M., Schreiber, R. D., Carlos de la Torre, J., & Oldstone, M. B. A. (2013) · Science · doi:10.1126/science.1235214 · Cited by 755
Resident memory CD8 T cells trigger protective innate and adaptive immune responses
Schenkel, J. M., Fraser, K. A., Beura, L. K., Pauken, K. E., Vezys, V., & Masopust, D. (2014) · Science · doi:10.1126/science.1254536 · Cited by 731
Self-citationBlockade of chronic type I interferon signaling to control persistent LCMV infection
Wilson, E. B., Yamada, D. H., Elsaesser, H., Herskovitz, J., Deng, J., Cheng, G., Aronow, B. J., Karp, C. L., & Brooks, D. G. (2013) · Science · doi:10.1126/science.1235208 · Cited by 709
Differentiation and Persistence of Memory CD8+ T Cells Depend on T Cell Factor 1
Zhou, X., Yu, S., Zhao, D.-M., Harty, J. T., Badovinac, V. P., & Xue, H.-H. (2010) · Immunity · doi:10.1016/j.immuni.2010.08.002 · Cited by 688
Tolerance and exhaustion: defining mechanisms of T cell dysfunction
Schietinger, A., & Greenberg, P. D. (2014) · Trends in Immunology · doi:10.1016/j.it.2013.10.001 · Cited by 673
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
Sharma, P., Wagner, K., Wolchok, J. D., & Allison, J. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3153 · Cited by 642
Selective expansion of a subset of exhausted CD8 T cells by αPD-L1 blockade
Blackburn, S. D., Shin, H., Freeman, G. J., & Wherry, E. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801497105 · Cited by 579
Self-citationMaster Transcription Factors Determine Cell-Type-Specific Responses to TGF-β Signaling
Mullen, A. C., Orlando, D. A., Newman, J. J., Lovén, J., Kumar, R. M., Bilodeau, S., Reddy, J., Guenther, M. G., DeKoter, R. P., & Young, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.08.050 · Cited by 570
IL-21 Is Required to Control Chronic Viral Infection
Elsaesser, H., Sauer, K., & Brooks, D. G. (2009) · Science · doi:10.1126/science.1174182 · Cited by 554
Doering, T. A., Crawford, A., Angelosanto, J. M., Paley, M. A., Ziegler, C. G., & Wherry, E. J. (2012) · Immunity · doi:10.1016/j.immuni.2012.08.021 · Cited by 548
Self-citationDurable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
Lipson, E. J., Sharfman, W. H., Drake, C. G., Wollner, I., Taube, J. M., Anders, R. A., Xu, H., Yao, S., Pons, A., Chen, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2625 · Cited by 545
Riches, J. C., Davies, J. K., McClanahan, F., Fatah, R., Iqbal, S., Agrawal, S., Ramsay, A. G., & Gribben, J. G. (2013) · Blood · doi:10.1182/blood-2012-09-457531 · Cited by 529
Patsoukis, N., Brown, J., Petkova, V., Liu, F., Li, L., & Boussiotis, V. A. (2012) · Science Signaling · doi:10.1126/scisignal.2002796 · Cited by 529
Iwai, Y. (2004) · International Immunology · doi:10.1093/intimm/dxh194 · Cited by 527
Quigley, M., Pereyra, F., Nilsson, B., Porichis, F., Fonseca, C., Eichbaum, Q., Julg, B., Jesneck, J. L., Brosnahan, K., Imam, S., et al. (2010) · Nature Medicine · doi:10.1038/nm.2232 · Cited by 517
Self-citationImmune Modulation in Cancer with Antibodies
Page, D. B., Postow, M. A., Callahan, M. K., Allison, J. P., & Wolchok, J. D. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-092012-112807 · Cited by 515
A Vital Role for Interleukin-21 in the Control of a Chronic Viral Infection
Yi, J. S., Du, M., & Zajac, A. J. (2009) · Science · doi:10.1126/science.1175194 · Cited by 504
Antigen-independent memory CD8 T cells do not develop during chronic viral infection
Wherry, E. J., Barber, D. L., Kaech, S. M., Blattman, J. N., & Ahmed, R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407192101 · Cited by 497
Self-citationMolecular and Transcriptional Basis of CD4+ T Cell Dysfunction during Chronic Infection
Crawford, A., Angelosanto, J. M., Kao, C., Doering, T. A., Odorizzi, P. M., Barnett, B. E., & Wherry, E. J. (2014) · Immunity · doi:10.1016/j.immuni.2014.01.005 · Cited by 496
Self-citationSustained Dysfunction of Antiviral CD8+T Lymphocytes after Infection with Hepatitis C Virus
Gruener, N. H., Lechner, F., Jung, M.-C., Diepolder, H., Gerlach, T., Lauer, G., Walker, B., Sullivan, J., Phillips, R., Pape, G. R., et al. (2001) · Journal of Virology · doi:10.1128/jvi.75.12.5550-5558.2001 · Cited by 495
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.
Strome, S. E., Dong, H., Tamura, H., Voss, S. G., Flies, D. B., Tamada, K., Salomão, D. R., Cheville, J. C., Hirano, F., Lin, W. Y., et al. (2003) · PubMed · Cited by 489
Kao, C., Oestreich, K. J., Paley, M. A., Crawford, A., Angelosanto, J. M., Ali, M.-A. A., Intlekofer, A. M., Boss, J. M., Reiner, S. L., Weinmann, A. S., et al. (2011) · Nature Immunology · doi:10.1038/ni.2046 · Cited by 484
Self-citationShin, H., Blackburn, S. D., Intlekofer, A. M., Kao, C., Angelosanto, J. M., Reiner, S. L., & Wherry, E. J. (2009) · Immunity · doi:10.1016/j.immuni.2009.06.019 · Cited by 481
Self-citationIL-21R on T Cells Is Critical for Sustained Functionality and Control of Chronic Viral Infection
Fröhlich, A., Kisielow, J., Schmitz, I., Freigang, S., Shamshiev, A. T., Weber, J., Marsland, B. J., Oxenius, A., & Kopf, M. (2009) · Science · doi:10.1126/science.1172815 · Cited by 450
PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines
Peng, W., Liu, C., Xu, C., Lou, Y., Chen, J., Yang, Y., Yagita, H., Overwijk, W. W., Lizée, G., Radvanyi, L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1187 · Cited by 432
Banerjee, A., Gordon, S. M., Intlekofer, A. M., Paley, M. A., Mooney, E. C., Lindsten, T., Wherry, E. J., & Reiner, S. L. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1002042 · Cited by 428
Self-citationYoungblood, B., Oestreich, K. J., Ha, S.-J., Duraiswamy, J., Akondy, R. S., West, E. E., Wei, Z., Lu, P., Austin, J. W., Riley, J. L., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.06.015 · Cited by 419
NFATc1 Regulates PD-1 Expression upon T Cell Activation
Oestreich, K. J., Yoon, H., Ahmed, R., & Boss, J. M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.4832 · Cited by 416
Staron, M. M., Gray, S. M., Marshall, H. D., Parish, I. A., Chen, J. H., Perry, C. J., Cui, G., Li, M. O., & Kaech, S. M. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.013 · Cited by 385
Nakamoto, N., Cho, H., Shaked, A., Olthoff, K., Valiga, M. E., Kaminski, M., Gostick, E., Price, D. A., Freeman, G. J., Wherry, E. J., et al. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000313 · Cited by 380
Self-citationIntegrating canonical and metabolic signalling programmes in the regulation of T cell responses
Pollizzi, K. N., & Powell, J. D. (2014) · Nature Reviews Immunology · doi:10.1038/nri3701 · Cited by 379
The role of the PD‐1 pathway in autoimmunity and peripheral tolerance
Fife, B. T., & Pauken, K. E. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05919.x · Cited by 355
Self-citationAt the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy
Callahan, M. K., & Wolchok, J. D. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1212631 · Cited by 348
Muenst, S., Soysal, S. D., Gao, F., Obermann, E. C., Oertli, D., & Gillanders, W. E. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2581-3 · Cited by 334
Xiao, Y., Yu, S., Zhu, B., Bedoret, D., Bu, X., Francisco, L. M., Hua, P., Duke-Cohan, J. S., Umetsu, D. T., Sharpe, A. H., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20130790 · Cited by 321
Viral persistence redirects CD4 T cell differentiation toward T follicular helper cells
Fahey, L. M., Wilson, E. B., Elsaesser, H., Fistonich, C. D., McGavern, D. B., & Brooks, D. G. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101773 · Cited by 320
Trompouki, E., Bowman, T. V., Lawton, L. N., Fan, Z. P., Wu, D.-C., DiBiase, A., Martin, C. S., Cech, J. N., Sessa, A. K., Leblanc, J. L., et al. (2011) · Cell · doi:10.1016/j.cell.2011.09.044 · Cited by 310
McMahan, R. H., Golden-Mason, L., Nishimura, M. I., McMahon, B. J., Kemper, M., Allen, T. M., Gretch, D. R., & Rosen, H. R. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43127 · Cited by 305
Features of responding T cells in cancer and chronic infection
Kim, P. S., & Ahmed, R. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.02.005 · Cited by 297
Buggert, M., Tauriainen, J., Yamamoto, T., Frederiksen, J., Ivarsson, M. A., Michaëlsson, J., Lund, O., Hejdeman, B., Jansson, M., Sönnerborg, A., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004251 · Cited by 296
Requirement for T-bet in the aberrant differentiation of unhelped memory CD8+ T cells
Intlekofer, A. M., Takemoto, N., Kao, C., Banerjee, A., Schambach, F., Northrop, J. K., Shen, H., Wherry, E. J., & Reiner, S. L. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070841 · Cited by 288
Self-citationShankar, P., Russo, M., Harnisch, B., Patterson, M., Skolnik, P., & Lieberman, J. (2000) · Blood · doi:10.1182/blood.v96.9.3094 · Cited by 285
Angelosanto, J. M., Blackburn, S. D., Crawford, A., & Wherry, E. J. (2012) · Journal of Virology · doi:10.1128/jvi.00889-12 · Cited by 285
Self-citationT cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion
Utzschneider, D. T., Legat, A., Fuertes Marraco, S. A., Carrié, L., Luescher, I., Speiser, D. E., & Zehn, D. (2013) · Nature Immunology · doi:10.1038/ni.2606 · Cited by 283
Ablation of CD8 and CD4 T Cell Responses by High Viral Loads
Fuller, M. J., & Zajac, A. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.1.477 · Cited by 276
Viral antigen and extensive division maintain virus-specific CD8 T cells during chronic infection
Shin, H., Blackburn, S. D., Blattman, J. N., & Wherry, E. J. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061937 · Cited by 273
Self-citationMumprecht, S., Schürch, C., Schwaller, J., Solenthaler, M., & Ochsenbein, A. F. (2009) · Blood · doi:10.1182/blood-2008-09-179697 · Cited by 267
PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis
Zinselmeyer, B. H., Heydari, S., Sacristán, C., Nayak, D., Cammer, M., Herz, J., Cheng, X., Davis, S. J., Dustin, M. L., & McGavern, D. B. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20121416 · Cited by 258
Duraiswamy, J., Ibegbu, C. C., Masopust, D., Miller, J. D., Araki, K., Doho, G. H., Tata, P., Gupta, S., Zilliox, M. J., Nakaya, H. I., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1001783 · Cited by 246
Zhang, Y., Huang, S., Gong, D., Qin, Y., & Shen, Q. (2010) · Cellular & Molecular Immunology · doi:10.1038/cmi.2010.28 · Cited by 241
Honda, T., Egen, J. G., Lämmermann, T., Kastenmüller, W., Torabi-Parizi, P., & Germain, R. N. (2014) · Immunity · doi:10.1016/j.immuni.2013.11.017 · Cited by 237
Human prostate‐infiltrating CD8+ T lymphocytes are oligoclonal and PD‐1+
Sfanos, K. S., Bruno, T. C., Meeker, A. K., De Marzo, A. M., Isaacs, W. B., & Drake, C. G. (2009) · The Prostate · doi:10.1002/pros.21020 · Cited by 233
Brooks, D. G., Teyton, L., Oldstone, M. B. A., & McGavern, D. B. (2005) · Journal of Virology · doi:10.1128/jvi.79.16.10514-10527.2005 · Cited by 233
Escaping High Viral Load Exhaustion
Reignat, S., Webster, G. J. M., Brown, D., Ogg, G. S., King, A., Seneviratne, S. L., Dusheiko, G., Williams, R., Maini, M. K., & Bertoletti, A. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011723 · Cited by 218
Oxenius, A., Price, D. A., Günthard, H. F., Dawson, S. J., Fagard, C., Perrin, L., Fischer, M., Weber, R., Plana, M., García, F., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202372199 · Cited by 212
Goepfert, P. A., Bansal, A., Edwards, B. H., Ritter, G. D., Tellez, I., McPherson, S. A., Sabbaj, S., & Mulligan, M. J. (2000) · Journal of Virology · doi:10.1128/jvi.74.21.10249-10255.2000 · Cited by 197
Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin
Curran, M. A., Geiger, T. L., Montalvo, W., Kim, M., Reiner, S. L., Al-Shamkhani, A., Sun, J. C., & Allison, J. P. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20121190 · Cited by 187
Kostense, S., Ogg, G. S., Manting, E. H., Gillespie, G. M. A., Joling, J., Vandenberghe, K., Veenhof, E. Z., van Baarle, D., Jurriaans, S., Klein, M. R., et al. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200103)31:3<677::aid-immu677>3.0.co;2-m · Cited by 182
Youngblood, B., Noto, A., Porichis, F., Akondy, R. S., Ndhlovu, Z. M., Austin, J. W., Bordi, R., Procopio, F. A., Miura, T., Allen, T. M., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203161 · Cited by 171
Rescued Tolerant CD8 T Cells Are Preprogrammed to Reestablish the Tolerant State
Schietinger, A., Delrow, J. J., Basom, R. S., Blattman, J. N., & Greenberg, P. D. (2012) · Science · doi:10.1126/science.1214277 · Cited by 169
Lu, P., Youngblood, B., Austin, J. W., Mohammed, A. U. R., Butler, R., Ahmed, R., & Boss, J. M. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20130208 · Cited by 165
Oxenius, A., Zinkernagel, R. M., & Hengartner, H. (1998) · Immunity · doi:10.1016/s1074-7613(00)80628-7 · Cited by 162
PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients
Fourcade, J., Kudela, P., Sun, Z., Shen, H., Land, S. R., Lenzner, D., Guillaume, P., Luescher, I. F., Sander, C., Ferrone, S., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803245 · Cited by 161
Radoja, S., Saio, M., Schaer, D., Koneru, M., Vukmanovic, S., & Frey, A. B. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.9.5042 · Cited by 160
Mueller, S. N., Vanguri, V. K., Ha, S.-J., West, E. E., Keir, M. E., Glickman, J. N., Sharpe, A. H., & Ahmed, R. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40040 · Cited by 160
Pilon‐Thomas, S., Mackay, A., Vohra, N. A., & Mulé, J. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0904114 · Cited by 150
Impact of Epitope Escape on PD-1 Expression and CD8 T-Cell Exhaustion during Chronic Infection
Blattman, J. N., Wherry, E. J., Ha, S., der Most, R. G. V., & Ahmed, R. (2009) · Journal of Virology · doi:10.1128/jvi.02524-08 · Cited by 143
Self-citationGranzyme B Promotes Cytotoxic Lymphocyte Transmigration via Basement Membrane Remodeling
Prakash, M. D., Munoz, M. A., Jain, R., Tong, P. L., Koskinen, A. M. L., Regner, M., Kleifeld, O., Ho, B. K., Olson, M. R., Turner, S. J., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.11.012 · Cited by 129
Mechanisms of resistance to BCR–ABL TKIs and the therapeutic strategies: A review
Yang, K., & Fu, L. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.11.001 · Cited by 109
Epigenetic Manipulation Restores Functions of Defective CD8+ T Cells From Chronic Viral Infection
Zhang, F., Zhou, X., DiSpirito, J. R., Wang, C., Wang, Y., & Shen, H. (2014) · Molecular Therapy · doi:10.1038/mt.2014.91 · Cited by 97
Pauken, K. E., Jenkins, M. K., Azuma, M., & Fife, B. T. (2013) · Diabetes · doi:10.2337/db12-1475 · Cited by 89
Self-citationShaping the repertoire of tumor‐infiltrating effector and regulatory T cells
Savage, P. A., Leventhal, D. S., & Malchow, S. (2014) · Immunological Reviews · doi:10.1111/imr.12166 · Cited by 86
Epitope Escape Mutation and Decay of Human Immunodeficiency Virus Type 1-Specific CTL Responses
Jamieson, B. D., Yang, O. O., Hultin, L. E., Hausner, M. A., Hultin, P. M., Matud, J. L., Kunstman, K., Killian, M. S., Altman, J. D., Kommander, K., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.10.5372 · Cited by 72
Obar, J. J., Fuse, S., Leung, E. K., Bellfy, S. C., & Usherwood, E. J. (2006) · Journal of Virology · doi:10.1128/jvi.00237-06 · Cited by 52
Alter, G., Hatzakis, G., Tsoukas, C. M., Pelley, K., Rouleau, D., LeBlanc, R. P., Baril, J.-G., Dion, H., Lefebvre, E. A., Thomas, R., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.1.477 · Cited by 48
Paley, M., Gordon, S. M., Bikoff, E. K., Robertson, E. J., Wherry, E. J., & Reiner, S. L. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0812400 · Cited by 34
Self-citation
Cited by
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
Self-citationLag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096
Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment
Azizi, E., Carr, A. J., Plitas, G., Cornish, A. E., Konopacki, C., Prabhakaran, S., Nainys, J., Wu, K., Kiseliovas, V., Setty, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.060 · Cited by 1,976
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
McLane, L. M., Abdel-Hakeem, M. S., & Wherry, E. J. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055318 · Cited by 1,975
Self-citation
Metadata
- Authors
- Pauken, K. E., & Wherry, E. J.
- Venue
- Trends in Immunology
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 36
- Issue
- 4
- Pages
- 265-276
- ISSN
- 1471-4906 (ISSN-L)
- OpenAlex
- W2110305039
- Cited by
- 1,171
- References
- 136
- FWCI
- 10.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.